214:, which initially acquired 8% of the company. It dedicated 65 employees to develop stem cell treatments for bone and cartilage disorders, including underwriting the cost of clinical trials, an arrangement that lasted until at least 1999. At the time, osteoporosis and arthritis were the top targets of Novartis research. The only direct competitor of Osiris at the time was a unit of Novartis, Systemix, which focused on stem cell treatments for cancer. Systemix was outside the scope of the deal Osiris had struck with Novartis. At the time, Osiris held also a majority stake in Gryphon, a blood stem cell technology exploitation firm spun out of
159:
22:
228:
In 2006, when the company had 84 employees, Jeffries and Lazard
Capital market took Osiris public, on NASDAQ, offering up 13% of the company as shares and raising $ 38.5 million, with funds intended for research, product development, loan servicing and clinical trial expenses. C. Randall Mills was
244:(GvHD). In 2013, Osiris sold its MSC drug and associated patents to Mesoblast of Australia and the drug was renamed Ryoncil. Osiris had spent more than two decades working on this product and the proceeds from this sale allowed the company to focus on a line of wound-healing projects.
195:
of fertility, resurrection, and the afterlife. Early financing was provided by a number of entities, including Three Arch Bay Health
Sciences Fund and Spencer Trask & Co. By 1994, the state of Maryland provided a loan and equity investment to lure the company from Ohio in 1995.
229:
CEO. At the time of the IPO, Osiris was considered to be "the closest in (the United States) to bring a pure stem cell product to the market", with a marketed drug for bone regeneration called
Osteocel. The company sold Osteocel to
275:, a global medical technology business. The company had $ 142 million in revenues for 2018 and 360 employees, all of whom were expected to remain with the firm, which would operate as a subsidiary to its parent.
247:
Osiris transitioned from product research to commercialization with the introduction of
Osteocel, Graphix, Stravix, and Chondrogen. In 2016, CEO, Lode Debrabandere, resigned. He was succeeded by the company's
303:
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (2 April 1999). "Multilineage
Potential of Adult Human Mesenchymal Stem Cells".
341:
This article includes description of the adult stem cell harvesting method that provided Osiris a competitive advantage over other firms in being able to productively support clinical trials.
834:
552:
Osiris
Therapeutics, Inc. Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, for the Fiscal Year Ended December 31, 2012, UNITED STATES SECURITIES AND EXCHANGE COMMISSION
225:
was co-founder James Burns, who held the position from the company's inception through at least 1999. The company's Chief
Financial Officer around this time was Michael Demchuk Jr.
756:
286:. Based on the results, the FDA approved a Phase 2/3 study on 300 patients at 30 sites around the U.S. The Cardiothoracic Surgical Trials Network, funded by the
881:
199:
A peer company, StemCells, emerged in 1995 in
California with a focus on neural regeneration, but using stem cell technology emerging from the laboratory of
876:
525:
39:
722:
698:
31:
734:
236:
In 2010, Osiris received the first regulatory clearance in the world for a systemically administered stem cell drug, called
283:
871:
460:
279:
233:
in 2009 for an upfront payment of $ 35 million at closing, and an additional $ 50 million in milestone payments.
180:
287:
268:, after being granted additional time for compliance. The company was relisted on the NASDAQ in August 2018.
215:
264:
stock exchange as the company failed to meet the exchange's requirements, including failure to file an
804:
452:
241:
412:
158:
723:
https://www.osiris.com/wp-content/uploads/2018/07/2018-08-01-Osiris-Relisting-on-NASDAQ-FINAL.pdf
222:
249:
210:
The year 1997 saw the start of a multi-million dollar research and licensing arrangement with
272:
172:
43:
833:
803:
669:
314:
8:
512:
491:
398:
377:
204:
318:
810:
621:
568:
188:
84:
445:
779:
674:
645:
613:
496:
456:
417:
382:
330:
305:
183:
in
Cleveland Ohio. Dr. Caplan contributed a license to certain technology and joined
774:
640:
625:
835:"Clinical Trials Of Mesoblast's Stem Cell Treatment For COVID-19 Set To Begin Soon"
603:
563:
322:
326:
200:
184:
290:, and Mesoblast (the owner of the product) commenced that trial on May 5, 2020.
282:
in New York City on late-stage, ventilator-assisted Covid-19 patients suffering
865:
617:
530:
176:
473:
334:
608:
591:
253:
191:, and Peter Friedli, as lead investor, to launch Osiris, named after the
526:"Osiris transfers Osteocel to NuVasive; UK biotech continues to suffer;"
757:"Smith & Nephew Completes Acquisition of Osiris Therapeutics, Inc"
265:
237:
252:, Dwayne Montgomery, then David and then Linda Palczuk, formerly of
805:"More Coronavirus Vaccines and Treatments Move Toward Human Trials"
298:
Affiliation of all authors was with Osiris unless otherwise noted.
257:
230:
211:
840:
261:
192:
302:
171:
was founded in March 1993 following the identification of
147:
492:"Maryland companies near regeneration of tissue, bone"
513:
Maryland companies increase role in cell regeneration
138:
Grafix, Stravix, Cartiform, BIO4, Osteocel, Prochymal
737:(Press release). Osiris Therapeutics. 13 March 2017
256:. In March 2017, shares of Osiris were temporarily
444:
278:Ryoncil was tested in a March 2020 pilot study at
271:In 2019, Osiris was acquired for $ 660 million by
735:"Osiris Receives Notice Of Delisting From NASDAQ"
240:or remestemcel-L. IIt was approved for pediatric
863:
592:"Mesoblast acquires Osiris' stem cell business"
802:Sheikh, Knvul; Thomas, Katie (8 April 2020).
759:(Press release). Smith+Nephew. 17 April 2019.
882:Pharmaceutical companies established in 1992
801:
670:"Osiris Therapeutics receives Nasdaq notice"
641:"Osiris Therapeutics to sell stem-cell drug"
775:"Columbia biotech company's sale finalized"
564:"Prochymal - First Stem Cell Drug Approved"
413:"New CEO at Osiris toiling as clock ticks"
157:
667:
607:
399:Cell research led to Osiris Therapeutics
877:Health care companies based in Maryland
489:
485:
483:
375:
864:
699:"Nasdaq to delist Osiris Therapeutics"
561:
831:
768:
766:
672:. Business Maryland: Daily Briefing.
668:Mirabella, Lorraine (23 March 2016).
638:
589:
772:
696:
480:
442:
438:
436:
410:
371:
369:
367:
365:
363:
361:
359:
357:
44:move details into the article's body
15:
284:Acute Respiratory Distress Syndrome
13:
763:
703:S&P Global Market Intelligence
661:
14:
893:
433:
421:. pp. C1, C9 (not available)
411:Bell, Julie (26 September 2002).
404:
354:
773:Cohn, Meredith (19 April 2019).
639:Dance, Scott (12 October 2013).
20:
825:
795:
749:
727:
716:
697:Irum, Tayyeba (10 March 2017).
690:
490:Guidera, Mark (11 April 1999).
293:
181:Case Western Reserve University
632:
583:
555:
546:
518:
376:Guidera, Mark (29 June 1997).
127:Dr. Arnold Caplan (Co-Founder)
1:
562:Rattue, Petra (22 May 2012).
347:
288:National Institutes of Health
223:chief executive officer (CEO)
173:mesenchymal stem cells (MSCs)
327:10.1126/science.284.5411.143
216:Johns Hopkins Medical School
187:, James S. Burns, a biotech
129:Kevin Kimberlin (Co-Founder)
7:
791:– via Newspapers.com.
686:– via Newspapers.com.
590:Waltz, Emily (2013-12-01).
508:– via Newspapers.com.
394:– via Newspapers.com.
10:
898:
832:Knapp, Alex (2 May 2020).
657:– via Nwspapers.com.
378:"From cells arises Osiris"
443:Hall, Stephen S. (2003).
397:Second part of article: "
242:Graft-versus-Host Disease
169:Osiris Therapeutics, Inc.
142:
134:
95:
79:
71:
872:Regenerative biomedicine
447:Merchants of Immortality
125:James Burns (Co-Founder)
63:Medical research company
273:Smith & Nephew plc
250:chief business officer
609:10.1038/nbt1213-1061
596:Nature Biotechnology
511:Part 2 of article: "
280:Mount Sinai Hospital
221:The company's first
319:1999Sci...284..143P
205:Stanford University
68:
67:Osiris Therapeutics
811:The New York Times
569:Medical News Today
189:venture capitalist
179:and colleagues at
85:Columbia, Maryland
66:
780:The Baltimore Sun
675:The Baltimore Sun
646:The Baltimore Sun
500:. pp. D1, D8
497:The Baltimore Sun
451:. United States:
418:The Baltimore Sun
386:. pp. D1, D2
383:The Baltimore Sun
166:
165:
119:Alla Danilkovitch
61:
60:
40:length guidelines
889:
853:
852:
850:
848:
837:
829:
823:
822:
820:
818:
807:
799:
793:
792:
790:
788:
770:
761:
760:
753:
747:
746:
744:
742:
731:
725:
720:
714:
713:
711:
709:
694:
688:
687:
685:
683:
665:
659:
658:
656:
654:
636:
630:
629:
611:
587:
581:
580:
578:
576:
559:
553:
550:
544:
543:
541:
539:
522:
516:
509:
507:
505:
487:
478:
477:
471:
469:
453:Houghton Mifflin
450:
440:
431:
430:
428:
426:
408:
402:
395:
393:
391:
373:
338:
162:
161:
154:
151:
149:
123:
117:
111:
105:
69:
65:
56:
53:
47:
38:Please read the
24:
23:
16:
897:
896:
892:
891:
890:
888:
887:
886:
862:
861:
859:
857:
856:
846:
844:
830:
826:
816:
814:
800:
796:
786:
784:
771:
764:
755:
754:
750:
740:
738:
733:
732:
728:
721:
717:
707:
705:
695:
691:
681:
679:
666:
662:
652:
650:
637:
633:
588:
584:
574:
572:
560:
556:
551:
547:
537:
535:
534:. 30 March 2009
524:
523:
519:
510:
503:
501:
488:
481:
467:
465:
463:
441:
434:
424:
422:
409:
405:
396:
389:
387:
374:
355:
350:
313:(5411): 143–7.
296:
201:Irving Weissman
185:Kevin Kimberlin
156:
146:
130:
128:
126:
124:
121:
120:
118:
115:
114:
112:
109:
108:
106:
103:
102:
98:
91:
87:
75:Pharmaceuticals
64:
57:
51:
48:
37:
34:may be too long
29:This article's
25:
21:
12:
11:
5:
895:
885:
884:
879:
874:
855:
854:
824:
794:
762:
748:
726:
715:
689:
660:
631:
582:
554:
545:
517:
479:
461:
432:
403:
352:
351:
349:
346:
345:
344:
343:
342:
295:
292:
164:
163:
144:
140:
139:
136:
132:
131:
99:
96:
93:
92:
89:
83:
81:
77:
76:
73:
62:
59:
58:
28:
26:
19:
9:
6:
4:
3:
2:
894:
883:
880:
878:
875:
873:
870:
869:
867:
860:
843:
842:
836:
828:
813:
812:
806:
798:
782:
781:
776:
769:
767:
758:
752:
736:
730:
724:
719:
704:
700:
693:
677:
676:
671:
664:
648:
647:
642:
635:
627:
623:
619:
615:
610:
605:
601:
597:
593:
586:
571:
570:
565:
558:
549:
533:
532:
531:FierceBiotech
527:
521:
514:
499:
498:
493:
486:
484:
475:
464:
462:0-618-09524-1
458:
454:
449:
448:
439:
437:
420:
419:
414:
407:
400:
385:
384:
379:
372:
370:
368:
366:
364:
362:
360:
358:
353:
340:
339:
336:
332:
328:
324:
320:
316:
312:
308:
307:
301:
300:
299:
291:
289:
285:
281:
276:
274:
269:
267:
266:annual report
263:
259:
255:
251:
245:
243:
239:
234:
232:
226:
224:
219:
217:
213:
208:
206:
202:
197:
194:
190:
186:
182:
178:
177:Arnold Caplan
174:
170:
160:
153:
145:
141:
137:
133:
113:Frank Czworka
101:Peter Friedli
100:
94:
90:United States
86:
82:
78:
74:
70:
55:
45:
41:
35:
33:
27:
18:
17:
858:
845:. Retrieved
839:
827:
815:. Retrieved
809:
797:
785:. Retrieved
783:. p. 10
778:
751:
739:. Retrieved
729:
718:
706:. Retrieved
702:
692:
680:. Retrieved
678:. p. 10
673:
663:
651:. Retrieved
649:. p. 10
644:
634:
602:(12): 1061.
599:
595:
585:
573:. Retrieved
567:
557:
548:
536:. Retrieved
529:
520:
502:. Retrieved
495:
474:Open Library
472:– via
466:. Retrieved
446:
423:. Retrieved
416:
406:
388:. Retrieved
381:
310:
304:
297:
294:Publications
277:
270:
246:
235:
227:
220:
209:
198:
193:Egyptian god
168:
167:
80:Headquarters
49:
32:lead section
30:
254:AstraZeneca
866:Categories
348:References
104:(Chairman)
97:Key people
52:March 2024
847:13 August
817:13 August
787:16 August
741:14 August
708:14 August
682:16 August
653:16 August
618:1546-1696
575:13 August
538:15 August
504:15 August
468:17 August
425:14 August
390:15 August
260:from the
238:Prochymal
42:and help
626:32036070
335:10102814
258:delisted
231:NuVasive
212:Novartis
135:Products
107:Greg Law
72:Industry
315:Bibcode
306:Science
175:by Dr.
150:.osiris
143:Website
841:Forbes
624:
616:
459:
333:
262:NASDAQ
155:
622:S2CID
122:(CSO)
116:(COO)
110:(CFO)
849:2020
819:2020
789:2022
743:2022
710:2022
684:2022
655:2022
614:ISSN
577:2020
540:2022
506:2022
470:2022
457:ISBN
427:2002
392:2022
331:PMID
152:.com
604:doi
323:doi
311:284
203:at
148:www
868::
838:.
808:.
777:.
765:^
701:.
643:.
620:.
612:.
600:31
598:.
594:.
566:.
528:.
494:.
482:^
455:.
435:^
415:.
380:.
356:^
329:.
321:.
309:.
218:.
207:.
88:,
851:.
821:.
745:.
712:.
628:.
606::
579:.
542:.
515:"
476:.
429:.
401:"
337:.
325::
317::
54:)
50:(
46:.
36:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
